{
  "ticker": "NUZ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958630",
  "id": "02958630",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250616",
  "time": "0932",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06ks3st66b5z1r.pdf",
  "summary": "### Summary of Material Information:  \n(Preclinical Data Announcement)  \n\n- **NUZ-001 and NUZ-001 Sulfone** demonstrated **neuroprotective effects** in a **zebrafish model of Huntington\u2019s disease (HD)**, including:  \n  - Prevention of developmental/morphological abnormalities.  \n  - Reduction in neuronal cell death.  \n  - Restoration of haemoglobin production and BDNF expression.  \n- **Next steps**: Additional validation in **mammalian HD models** planned.  \n- **Broader implications**: Supports NUZ-001\u2019s potential as a **platform therapy** for neurodegenerative diseases (beyond ALS).  \n\n*No financial, trading, or capital structure impacts disclosed.*",
  "usage": {
    "prompt_tokens": 2466,
    "completion_tokens": 147,
    "total_tokens": 2613,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T23:45:09.454802"
}